Lilly takes the lead
According to Reuters, China’s medicine regulator announced the approval on Thursday. Lilly was the first company to apply for approval of a weight-loss pill in China, while Novo Nordisk’s application for oral Wegovy was only accepted for review in August 2026.
The approval marks an important step in Lilly’s global strategy. After the FDA approved Foundayo on April 1, 2026, following a review of just 50 days, the fastest for a new molecular entity since 2002, the company filed applications in more than 40 countries and pledged to launch as soon as each approval came through.
How does a pill differ from an injection?
Orforglipron belongs to the class of drugs that mimic the GLP-1 hormone, helping regulate appetite and prolong feelings of fullness. The difference lies in its structure and how it is used:
- It is a small molecule rather than a peptide, so it can be manufactured as a tablet at large scale.
- It is taken once a day, at any time, with no food or water restrictions.
- It requires no needles or refrigeration, unlike weekly injections.
- In the Phase 3 ATTAIN-1 trial, people on the highest dose lost on average about 12% of their body weight after 72 weeks.

















